About us
Our products
Lundbeck corporate
Lundbeck.com
Home
Sitemap
Search
Contact
Country websites
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
Chile
Czech Republic
Denmark
Estonia
Finland
Germany
Greece
Gulf countries
India
Ireland
Italy
Lundbeck Pharmaceuticals Italy
Japan
Korea
Latvia
Mexico
Netherlands
Norway
Pakistan
Poland
Russia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
United States of America
Venezuela
Our products
Cipralex
Ebixa
Azilect
Serdolect
Circadin
Our therapy areas
Depression
Anxiety
Alzheimer's disease
Parkinson's disease
Schizophrenia
Insomnia
Other Lundbeck sites
CNSForum
Cipralex.com
Ebixa.com
Azilect.com
Serdolect.com
DepNet.com
DementiaNet
Brainexplorer
Patient Support Programme (iCan)
Psychotropics online
Sleep problems
My PD info
Annual report 2009
Order printed material
Employee profiles
Patient information
Pipeline
Partnering with us
Lundbeck A/S (LUN)
89.50 DKK -0.35
at 16:59:35
OMX Copenhagen 20 (OMXC20)
406.71 -2.20
at 16:59:35
Latest releases
First half report 2010 - Lundbeck reports strongly increasing profits with EBIT growth of 30%
13-Aug-2010
TEMPO study further demonstrates the benefits of Azilect® in early Parkinson's disease patients
05-Aug-2010
View all releases
s.a. Lundbeck n.v.
Avenue Molière laan 225
B-1050 Bruxelles/Brussel
Tel +32 2 340 28 28
Fax +32 2 346 47 77
Specialists in psychiatry - Pioneers in neurology
Disclaimer & privacy statement